An2 Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
AN2 Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 3, 2026, to elect directors and ratify auditors.
NASDAQ
AN2 Therapeutics will hold its annual stockholders meeting on May 22, 2025, to elect directors and ratify the appointment of PricewaterhouseCoopers LLP as its independent accounting firm.
NASDAQ
AN2 Therapeutics will hold its 2025 Annual Meeting of Stockholders on May 22, 2025, to elect directors and ratify the appointment of its independent registered public accounting firm.
NASDAQ
AN2 Therapeutics sets date for annual stockholders meeting on June 19, 2024, with key proposals including director elections and ratification of PricewaterhouseCoopers LLP as auditor.
NASDAQ
AN2 Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 19, 2024, to vote on the election of directors, ratification of the independent accounting firm, and amendment of the certificate of incorporation.